A combination of BRAF and MEK inhibitors plus immunotherapy improved progression-free but not overall survival, compared to dual immune checkpoint blockade.

EXEL gains 28.2% YTD, driven by Cabometyx growth, pipeline progress and an increase in stock buyback authorizations.

Delhi Police has busted a racket selling spurious anti-cancer drugs and arrested six men who targeted patients through social media by offering costly medicines at discounted rates, an official said ...

Delhi Police dismantled a network selling counterfeit anti-cancer drugs, arresting six men who exploited social media to target patients with fake medications at reduced prices. These drugs, including ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

The accused individuals were selling spurious cancer medicines and injections, including Opdivo, Pembrolizumab Injection, Keytruda, and others, without proper authorisation. The police raided three ...

Bristol-Myers Squibb (NYSE:BMY) recently announced a significant partnership with BioNTech SE to co-develop and ...

Despite its success in advanced melanoma, Bristol Myers Squibb’s fixed-dose PD-1/LAG-3 combo, Opdualag, failed to move the ...

Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with chemotherapy ...

Researchers at ASCO reviewing data from the ATOMIC trial said they will change practice based on the results but questioned ...

Nivolumab plus ipilimumab showed activity in mCRPC, and while adding SBRT was safe, it did not boost efficacy in the CheckPRO trial.

Postoperative nivolumab added to standard-of-care adjuvant cisplatin radiotherapy “represents a potential new standard.” ...